{"title":"14-3-3 - mpla -脂质体疫苗对小鼠囊性包虫病免疫保护作用的研究","authors":"Li ZongJi, Ding Shuqing, Li Yuan","doi":"10.1016/j.flm.2019.05.002","DOIUrl":null,"url":null,"abstract":"<div><p>The study aims to investigate the protective immunity against <em>Echinococcus granulosus</em> in mice immunized with14-3-3–MPLA–liposome vaccine. ICR (Institute of Cancer Research) mice were subcutaneously immunized three times with 14-3-3–MPLA–liposome vaccine, followed by the challenge with <em>Echinococcus granulosus</em> protoscoleces intraperitoneally and then sacrificed after six months of post-challenge. The levels of IL-4, and IFN-γ were measured by ELISA. The rate of reduced hydatid cyst and the levels of IgE, IgG and IgG subclasses in sera were examined. The result showed that mice vaccinated with14-3-3–MPLA–liposome vaccine and challenged with protoscoleces revealed significant protective immunity of 95.07%. ELISA analysis indicated that the immunized mice generated specific high levels of IgG and the prevailing isotypes of IgG were IgG1 and IgG2a. The level of IFN-γ increased significantly in the vaccinated mice whereas there was no significant difference in IL-4 levels between vaccinated and control mice. It is concluded that the14-3-3–MPLA–liposome vaccine could induce a high level of protective immunity to prevent cystic echinococcosis. The MPLA and liposome are promising vaccine adjuvant and delivery system.</p></div>","PeriodicalId":100555,"journal":{"name":"Frontiers in Laboratory Medicine","volume":"2 4","pages":"Pages 146-151"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.flm.2019.05.002","citationCount":"6","resultStr":"{\"title\":\"Study on the immunity protection of 14-3-3–MPLA–liposome vaccine against cystic echinococcosis in mice\",\"authors\":\"Li ZongJi, Ding Shuqing, Li Yuan\",\"doi\":\"10.1016/j.flm.2019.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The study aims to investigate the protective immunity against <em>Echinococcus granulosus</em> in mice immunized with14-3-3–MPLA–liposome vaccine. ICR (Institute of Cancer Research) mice were subcutaneously immunized three times with 14-3-3–MPLA–liposome vaccine, followed by the challenge with <em>Echinococcus granulosus</em> protoscoleces intraperitoneally and then sacrificed after six months of post-challenge. The levels of IL-4, and IFN-γ were measured by ELISA. The rate of reduced hydatid cyst and the levels of IgE, IgG and IgG subclasses in sera were examined. The result showed that mice vaccinated with14-3-3–MPLA–liposome vaccine and challenged with protoscoleces revealed significant protective immunity of 95.07%. ELISA analysis indicated that the immunized mice generated specific high levels of IgG and the prevailing isotypes of IgG were IgG1 and IgG2a. The level of IFN-γ increased significantly in the vaccinated mice whereas there was no significant difference in IL-4 levels between vaccinated and control mice. It is concluded that the14-3-3–MPLA–liposome vaccine could induce a high level of protective immunity to prevent cystic echinococcosis. The MPLA and liposome are promising vaccine adjuvant and delivery system.</p></div>\",\"PeriodicalId\":100555,\"journal\":{\"name\":\"Frontiers in Laboratory Medicine\",\"volume\":\"2 4\",\"pages\":\"Pages 146-151\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.flm.2019.05.002\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Laboratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2542364919300123\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542364919300123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Study on the immunity protection of 14-3-3–MPLA–liposome vaccine against cystic echinococcosis in mice
The study aims to investigate the protective immunity against Echinococcus granulosus in mice immunized with14-3-3–MPLA–liposome vaccine. ICR (Institute of Cancer Research) mice were subcutaneously immunized three times with 14-3-3–MPLA–liposome vaccine, followed by the challenge with Echinococcus granulosus protoscoleces intraperitoneally and then sacrificed after six months of post-challenge. The levels of IL-4, and IFN-γ were measured by ELISA. The rate of reduced hydatid cyst and the levels of IgE, IgG and IgG subclasses in sera were examined. The result showed that mice vaccinated with14-3-3–MPLA–liposome vaccine and challenged with protoscoleces revealed significant protective immunity of 95.07%. ELISA analysis indicated that the immunized mice generated specific high levels of IgG and the prevailing isotypes of IgG were IgG1 and IgG2a. The level of IFN-γ increased significantly in the vaccinated mice whereas there was no significant difference in IL-4 levels between vaccinated and control mice. It is concluded that the14-3-3–MPLA–liposome vaccine could induce a high level of protective immunity to prevent cystic echinococcosis. The MPLA and liposome are promising vaccine adjuvant and delivery system.